AstraZeneca's Vaxzevria Gets Full Marketing Authorization in EU for Prevention of Covid-19
2022年11月1日 - 04:41PM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Tuesday that its Covid-19 vaccine Vaxzevria
has been granted full marketing authorization in the European
Union.
The Anglo-Swedish pharmaceutical giant said Vaxzevria has been
shown to be effective against all forms of Covid-19.
"The move from conditional to full marketing authorization for
Vaxzevria is an important confirmation by the EMA of the safety and
efficacy of Vaxzevria, demonstrating that the benefits continue to
outweigh the potential risks," Iskra Reic, executive vice
president, vaccines and immune therapies at AstraZeneca, said.
Vaxzevria was originally granted conditional marketing
authorization due to the urgency of the Covid-19 pandemic, it
said.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
November 01, 2022 03:26 ET (07:26 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 2 2024 まで 3 2024
Astrazeneca (LSE:AZN)
過去 株価チャート
から 3 2023 まで 3 2024